This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lozano-Chiu, M.
Right arrow Articles by Rex, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lozano-Chiu, M.
Right arrow Articles by Rex, J. H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 1999, p. 589-591, Vol. 43, No. 3
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Treatment of Murine Fusariosis with SCH 56592

M. Lozano-Chiu,1,* S. Arikan,1 V. L. Paetznick,1 E. J. Anaissie,2 D. Loebenberg,3 and J. H. Rex1

Division of Infectious Diseases, Department of Internal Medicine, Center for the Study of Emerging and Reemerging Pathogens, University of Texas Medical School, Houston, Texas 770301; The Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas 772052; and Schering-Plough Research Institute, Kenilworth, New Jersey3

Received 1 October 1998/Returned for modification 9 November 1998/Accepted 4 December 1998

Doses of 10 to 100 mg of the azole antifungal agent SCH 56592/kg of body weight/day were studied in immunocompetent mice as therapy for systemic infection by Fusarium solani. Treatment was begun 1 h after intravenous infection and continued daily for 4 or 13 doses. Prolongation of survival and organ clearance were dependent on both the dose and the duration of SCH 56592 therapy, with the best results seen at 50 and 100 mg/kg/day. The results at the highest doses of SCH 56592 used (50 or 100 mg/kg/day) were comparable to those obtained with amphotericin B at 1 mg/kg/day. SCH 56592 has potential for therapy of systemic infections caused by F. solani.

* Corresponding author. Mailing address: 6431 Fannin, 1728 JFB, Houston, TX 77030. Phone: (713) 500-6755. Fax: (713) 500-5495. E-mail: mchiu{at}heart.med.uth.tmc.edu.

Antimicrobial Agents and Chemotherapy, March 1999, p. 589-591, Vol. 43, No. 3
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Marine, M., Pastor, F. J., Serena, C., Guarro, J. (2009). Efficacy of Triazoles in a Murine Disseminated Infection by Candida krusei. Antimicrob. Agents Chemother. 53: 3585-3588 [Abstract] [Full Text]  
  • Rodriguez, M. M., Pastor, F. J., Serena, C., Guarro, J. (2009). Posaconazole efficacy in a murine disseminated infection caused by Paecilomyces lilacinus. J Antimicrob Chemother 63: 361-364 [Abstract] [Full Text]  
  • Carrillo-Munoz, A.-J., Quindos, G., Ruesga, M., Alonso, R., del Valle, O., Hernandez-Molina, J. M., McNicholas, P., Loebenberg, D., Santos, P. (2005). Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections. J Antimicrob Chemother 55: 317-319 [Abstract] [Full Text]  
  • Simitsopoulou, M., Gil-Lamaignere, C., Avramidis, N., Maloukou, A., Lekkas, S., Havlova, E., Kourounaki, L., Loebenberg, D., Roilides, E. (2004). Antifungal Activities of Posaconazole and Granulocyte-Macrophage Colony-Stimulating Factor Ex Vivo and in Mice with Disseminated Infection Due to Scedosporium prolificans. Antimicrob. Agents Chemother. 48: 3801-3805 [Abstract] [Full Text]  
  • Paphitou, N. I., Ostrosky-Zeichner, L., Paetznick, V. L., Rodriguez, J. R., Chen, E., Rex, J. H. (2002). In Vitro Activities of Investigational Triazoles against Fusarium Species: Effects of Inoculum Size and Incubation Time on Broth Microdilution Susceptibility Test Results. Antimicrob. Agents Chemother. 46: 3298-3300 [Abstract] [Full Text]  
  • Barchiesi, F., Schimizzi, A. M., Najvar, L. K., Bocanegra, R., Caselli, F., Di Cesare, S., Giannini, D., Di Francesco, L. F., Giacometti, A., Carle, F., Scalise, G., Graybill, J. R. (2001). Interactions of Posaconazole and Flucytosine against Cryptococcus neoformans. Antimicrob. Agents Chemother. 45: 1355-1359 [Abstract] [Full Text]  
  • Petraitiene, R., Petraitis, V., Groll, A. H., Sein, T., Piscitelli, S., Candelario, M., Field-Ridley, A., Avila, N., Bacher, J., Walsh, T. J. (2001). Antifungal Activity and Pharmacokinetics of Posaconazole (SCH 56592) in Treatment and Prevention of Experimental Invasive Pulmonary Aspergillosis: Correlation with Galactomannan Antigenemia. Antimicrob. Agents Chemother. 45: 857-869 [Abstract] [Full Text]  
  • Cacciapuoti, A., Loebenberg, D., Corcoran, E., Menzel, F. Jr., Moss, E. L. Jr., Norris, C., Michalski, M., Raynor, K., Halpern, J., Mendrick, C., Arnold, B., Antonacci, B., Parmegiani, R., Yarosh-Tomaine, T., Miller, G. H., Hare, R. S. (2000). In Vitro and In Vivo Activities of SCH 56592 (Posaconazole), a New Triazole Antifungal Agent, against Aspergillus and Candida. Antimicrob. Agents Chemother. 44: 2017-2022 [Abstract] [Full Text]  
  • Molina, J., Martins-Filho, O., Brener, Z., Romanha, A. J., Loebenberg, D., Urbina, J. A. (2000). Activities of the Triazole Derivative SCH 56592 (Posaconazole) against Drug-Resistant Strains of the Protozoan Parasite Trypanosoma (Schizotrypanum) cruzi in Immunocompetent and Immunosuppressed Murine Hosts. Antimicrob. Agents Chemother. 44: 150-155 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»